[SCHEDULE 13D/A] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Amendment No. 5 to Schedule 13D updates the ownership position of the reporting group — Skorpios Trust, Montrago Trustees Ltd., Blue Horizon Enterprise Ltd. and Ezbon International Ltd. — in Stoke Therapeutics (STOK).

The group now reports beneficial ownership of roughly 6.23 million shares, or 11.4 % of the 54.6 million shares outstanding as disclosed in STOK’s 30 April 2025 10-Q. Current individual blocks are:

• Blue Horizon: 2,967,621 shares (5.4 %) with shared voting/dispositive power
• Montrago Trustees & Skorpios Trust: 3,256,181 shares each, reflecting the same 6 % stake held jointly
• Ezbon International: 288,560 shares (0.5 %)

Key event: On 18 June 2025 Ezbon sold 650,000 shares at $11.00 in an open-market trade, cutting its holdings by ~69 % and raising about $7.2 million. No other trades were reported within the past 60 days.

A new Joint Filing Agreement dated 23 June 2025 is filed as Exhibit 1. Aside from Ezbon’s sale, prior disclosures remain unchanged.

While the group continues to exceed the 10 % threshold, Ezbon’s sizable disposal may signal reduced conviction or liquidity needs, and could introduce incremental supply pressure if additional sales follow. Investors should monitor forthcoming filings for further changes to this concentrated insider position.

Positive

• None.

Negative

• Ezbon International sold 650,000 shares (~69 % of its position, 1.2 % of shares outstanding) at $11, signalling reduced insider commitment and adding potential selling pressure.

Insights

Securities Analyst

TL;DR: Insider affiliate Ezbon offloaded 650 k shares; group still 11.4 % holder—net signal skews bearish.

Ezbon’s $7 m sale represents roughly a two-thirds reduction in its stake and 1.2 % of STOK’s float. Although the broader reporting group keeps an 11 % position, the disposal loosens internal alignment and adds potential overhang at the $11 level. With no stated strategic rationale, markets may interpret the move as profit-taking or waning enthusiasm ahead of catalysts. Continued selling by other group entities would be a clear negative for sentiment and liquidity.

Corporate Governance Expert

TL;DR: Governance impact limited; ownership structure intact despite one member’s sale.

The filing maintains transparency and renews the joint filing agreement, confirming that the entities act in concert. Even after Ezbon’s divestiture, the group retains >10 % voting power, preserving influence over corporate actions but avoiding triggering additional regulatory thresholds. No governance disputes or activist intentions are disclosed. Overall, neutral from a control-risk perspective.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

Stoke Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

86150R107

(CUSIP Number)

Patrik Blochlinger, Chief
Legal Officer, Rigmora (Switzerland) Ltd, Stockerstrasse 8
Zurich, V8, 8002
41 44 287 2498

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/18/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 86150R107

1

Name of reporting person

Blue Horizon Enterprise Ltd

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,967,621.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,967,621.00

11

Aggregate amount beneficially owned by each reporting person

2,967,621.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.4 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

The percentages used herein and in the rest of this Schedule 13D are calculated based upon 54,596,924 shares of the Issuer's common stock outstanding as of April 30, 2025, as reported in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2025.

SCHEDULE 13D

CUSIP No. 86150R107

1

Name of reporting person

Ezbon International Ltd

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 288,560.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 288,560.00

11

Aggregate amount beneficially owned by each reporting person

288,560.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.5 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 86150R107

1

Name of reporting person

Montrago Trustees Ltd

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CYPRUS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,256,181.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,256,181.00

11

Aggregate amount beneficially owned by each reporting person

3,256,181.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 86150R107

1

Name of reporting person

Skorpios Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CYPRUS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,256,181.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,256,181.00

11

Aggregate amount beneficially owned by each reporting person

3,256,181.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: Stoke Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 45 Wiggins Ave., Bedford, MASSACHUSETTS , 01730.
Item 1 Comment: This Amendment No. 5 (the "Amendment No. 5") is filed by Skorpios Trust, Montrago Trustees Limited ("Montrago Trustees"), Ezbon International Limited ("Ezbon") and Blue Horizon Enterprise Ltd. ("Blue Horizon" and, collectively, the "Reporting Persons") and amends the Schedule 13D filed by the Reporting Persons on June 30, 2021, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Persons on April 18, 2024, Amendment No. 2 to Schedule 13D filed by the Reporting Persons on September 23, 2024, Amendment No. 3 to Schedule 13D filed by the Reporting Persons on December 27, 2024 and Amendment No. 4 to Schedule 13D filed by the Reporting Persons on June 6, 2025 (as amended, the "Schedule 13D"). The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Schedule 13D.
Item 4.	Purpose of Transaction
	Item 4 is hereby amended and supplemented by adding the following: On June 18, 2025, Ezbon sold 650,000 Shares of the Issuer in an open market transaction at a price of $11.00 per share.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) is hereby amended and restated as follows: (a) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.
(b)	Item 5(b) is hereby amended and restated as follows: (b) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.
(c)	Item 5(c) is hereby amended and restated as follows: (c) The information reported in Item 4 is incorporated herein by reference. Other than as disclosed in that item, no transactions in the Shares have been effected by the Reporting Person during the past sixty (60) days.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Joint Filing Agreement, dated as of June 23, 2025, by and among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Horizon Enterprise Ltd

Signature:	/s/ Eleni Constantinou Kyriacou
Name/Title:	Eleni Constantinou Kyriacou, Director
Date:	06/23/2025

Ezbon International Ltd

Signature:	/s/ Eleni Constantinou Kyriacou
Name/Title:	Eleni Constantinou Kyriacou, Director
Date:	06/23/2025

Montrago Trustees Ltd

Signature:	/s/ Androulla Papadopoulou
Name/Title:	Androulla Papadopoulou, Director
Date:	06/23/2025

Skorpios Trust

Signature:	/s/ Androulla Papadopoulou
Name/Title:	Androulla Papadopoulou, Director
Date:	06/23/2025

FAQ

Why did Ezbon International Ltd. sell 650,000 STOK shares?

The filing only states that the shares were sold on 18 June 2025 in an open-market transaction at $11.00 per share; it does not provide a reason.

What is the insider group’s total ownership percentage in Stoke Therapeutics (STOK) after Amendment No. 5?

Approximately 11.4 % of the 54.6 million shares outstanding.

How many STOK shares does Blue Horizon Enterprise Ltd. currently hold?

Blue Horizon reports 2,967,621 shares, equal to 5.4 % of the outstanding common stock.

When did the joint filing agreement among the reporting persons become effective?

The new Joint Filing Agreement is dated 23 June 2025.

At what price were the 650,000 sold STOK shares transacted?

The shares were sold at $11.00 per share.